Five things for pharma marketers to know: Wednesday, January 17, 2018

Share this content:

Photo credit: Celgene

1. Less than a week after it acquired biotech Impact Biomedicines for up to $7 billion, Celgene is reportedly in talks to acquire biotech company Juno Therapeutics. Both drugmakers specialize in blood cancer treatments. (WSJ)

2. The FDA and European Medicines Agency granted fast-track reviews for Novartis' CAR-T therapy Kymriah, for the treatment of blood cancers. It competes with CAR-T therapies like Gilead's Yescarta, which the FDA approved for aggressive refractory adult lymphoma last October. (Reuters)

3. The FDA has approved a supplemental New Drug Application for Boehringer Ingelheim's lung cancer drug Gilotrif. The application is for the treatment of patients with metastatic non-small cell lung cancer whose tumors have non-resistant epidermal growth factor receptor. (PharmaTimes)

4. GV, Google's venture capital investment arm, is investing more than $27 million in British biotech Vaccitech. The company, an Oxford University spinoff, is developing universal flu and prostate cancer vaccines. (TechCrunch)

5. Babylon Healthcare's online doctor service GP at Hand, already approved and operating in London, may delay further expansion across the U.K. due to concerns about safety, clinical governance, and capacity to support more patients. (Pharmaphorum)

Share this content:
Scroll down to see the next article